120 Views | 56 Downloads
John Mascarenhas, Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029; e-mail: john.mascarenhas@mssm.edu
J.M., H.E.K., J.T.P., A.R., C.N.H., M.F.M., A.M.V., J.E., J.-J.K., R.T.S., R.S.W., L.P., J.D.G., T.B., R.M., G.T., R.A.M., A.C.D., and R.H. contributed to the design of the clinical trial; J.M., H.E.K., A.R., D.B., A.Y., C.N.H., M.F.M., A.M.V., J.E., C.L.O., J.-J.K., A.J.M., E.F.W., D.S.L., V.D.S., M.O.A., C.M.K., R.C., D.R., R.T.S., A.B., A.N., M.K., M.E.S., V.N., N.F., R.S.W., L.P., J.D.G., T.B., R.M., G.T., R.K.R., R.A.M., A.C.D., and R.H. wrote the manuscript; J.M., H.E.K., J.T.P., A.R., D.B., A.Y., C.N.H., M.F.M., A.M.V., J.E., C.L.O., J.-J.K., A.J.M., E.F.W., D.S.L., V.D.S., M.O.A., C.M.K., R.C., D.R., R.T.S., A.B., A.N., M.K., M.F.L., J.E.A.O., E.M., L.S., M.E.S., V.N., J.T., N.F., A.V.P., R.S.W., L.P., J.D.G., T.B., R.M., G.T., R.K.R., R.A.M., A.C.D., and R.H. contributed to patient recruitment, data collection, and analysis; H.E.K., L.P., J.D.G., and A.C.D. performed statistical analyses; and all authors gave final approval of the version to be published and agreed to be accountable for questions related to the accuracy and integrity of the work.
J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen Pharmaceuticals, Geron, Kartos, AbbVie, Merck, Promedior, PharmaEssentia, and Celgene/BMS and is a clinical trial steering committee member, scientific advisory board member, and consultant for Roche, CTI Biopharma, Constellation, Novartis, Galecto, PharmaEssentia, Sierra Oncology, AbbVie, Kartos, Incyte, and Celgene/BMS. reports clinical trial research support paid to the institution from AbbVie, AI, Astellas, Forma, Incyte, Kite, and Takeda. E.F.W. reports advisory boards for Incyte and Gilead Sciences. A.Y. reports consultation and speaker honoraria for Incyte, Seattle Genetics, and Novartis. A.R. reports consultation and speaker honoraria for Novartis, Amgen, Roche, Celgene, and Italfarmaco. A.M.V. reports speaker honoraria from Novartis and Celgene and fees for participation on advisory boards for Novartis, CTI, and Celgene. D.R. reports consulting honoraria from Incyte. M.O.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen Pharmaceuticals, and Gilead. R.T.S. reports consultancy and speaker bureau fees from Pharmaessentia. R.K.R. has received consulting fees from Stemline Corporation, Celgene, Agios Pharmaceuticals, Apexx Oncology, Beyond Spring, Partner Therapeutics, and Jazz Pharmaceuticals and has received research funding from Constellation Pharmaceuticals, Incyte, and Stemline Therapeutics. R.M. reports research support from Incyte, Genentech, CTI, Promedior, and AbbVie and is a consultant for Novartis, Sierra Oncology, and La Jolla Pharma. R.H. reports research support from Roche. The remaining authors declare no competing financial interests.
This work was supported by a grant from the National Cancer Institute, National Institutes of Health (MPN Research Consortium, 5P01CA108671-09), a Cancer Center Support Grant/Core grant to Memorial Sloan-Kettering Cancer Center (P30 CA008748), and generous independent, unrestricted support from Roche Genentech. R.K.R. is supported by the National Cancer Institute, National Institutes of Health (1K08CA188529-01).
© 2022 by The American Society of Hematology.